[(2R)-3-[2-formamidoethoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: [(2R)-3-[2-formamidoethoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate
• 化学式: C₄₂H₈₂NO₉P
• 分子量: 776.1
• InChiKey: DJFGMTQUNBUDBT-RRHRGVEJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15
• 重原子数：
  53
• 可旋转键数：
  44
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Pharmaceutical compositions of hydrophobic camptothecin derivatives
  申请人：Taiwan Liposome Company, Ltd.

  公开号：US10980798B2

  公开（公告）日：2021-04-20

  Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.

  提供一种在癌症治疗中使用拓扑异构酶 I 抑制剂以减少骨髓抑制的方法。该方法包括向有需要的受试者施用有效量的药物组合物。该组合物具有至少一种疏水性拓扑异构酶I抑制剂或其药学上可接受的盐，以及至少一种聚乙二醇(PEG)共轭磷脂，其中所述PEG共轭磷脂与所述疏水性拓扑异构酶I抑制剂或所述疏水性拓扑异构酶I抑制剂的药学上可接受的盐的摩尔比约为0.45:1至约1.05:1。
• TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
  申请人：Bussat Philippe

  公开号：US20080107607A1

  公开（公告）日：2008-05-08

  Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.
• PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES
  申请人：Taiwan Liposome Company, Ltd.

  公开号：US20140294973A1

  公开（公告）日：2014-10-02

  The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.
• US9295737B2
  申请人：——

  公开号：US9295737B2

  公开（公告）日：2016-03-29
• US9381258B2
  申请人：——

  公开号：US9381258B2

  公开（公告）日：2016-07-05